Last update 21 Nov 2024
Anti-mesothelin CAR-T cell therapy (Tmunity Therapeutics/University of Pennsylvania)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type CAR-T |
Synonyms AntiMSLN CAR T cell therapy, AntiMSLN chimeric antigen receptor T cell immunotherapy |
Target |
Mechanism MSLN inhibitors(Mesothelin inhibitors), Gene transference, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization  Tmunity Therapeutics, Inc.Startup |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
6
Clinical Trials associated with Anti-mesothelin CAR-T cell therapy (Tmunity Therapeutics/University of Pennsylvania)Phase 1, Adaptive-design Trial of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Breast Cancer
Phase 1 Trial of Human Chimeric Antigen Receptor Modified T Cells (huCART-meso) Administered in Combination With VCN-01 in Patients With Pancreatic and Serous Epithelial Ovarian Cancer
Phase I Study of Human Chimeric Antigen Receptor Modified T Cells (CAR T Cells) in Patients With Pancreatic Cancer
100 Clinical Results associated with Anti-mesothelin CAR-T cell therapy (Tmunity Therapeutics/University of Pennsylvania)
Login to view more data
100 Translational Medicine associated with Anti-mesothelin CAR-T cell therapy (Tmunity Therapeutics/University of Pennsylvania)
Login to view more data
100 Patents (Medical) associated with Anti-mesothelin CAR-T cell therapy (Tmunity Therapeutics/University of Pennsylvania)
Login to view more data
100 Deals associated with Anti-mesothelin CAR-T cell therapy (Tmunity Therapeutics/University of Pennsylvania)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Adenocarcinoma of Lung | Phase 1 | US | 06 Apr 2017 | |
| Fallopian Tube Carcinoma | Phase 1 | US | 06 Apr 2017 | |
| Malignant Mesothelioma of Peritoneum | Phase 1 | US | 06 Apr 2017 | |
| Malignant Pleural Mesothelioma | Phase 1 | US | 06 Apr 2017 | |
| Mesothelin positive Neoplasms | Phase 1 | US | 06 Apr 2017 | |
| Ovarian Cancer | Phase 1 | US | 06 Apr 2017 | |
| Peritoneal Neoplasms | Phase 1 | US | 06 Apr 2017 | |
| Ductus Arteriosus, Patent | Phase 1 | US | 01 Jul 2013 | |
| Lung Cancer | Discovery | US | 10 Dec 2020 | |
| Secondary malignant neoplasm of pancreas | Discovery | US | 01 Jul 2013 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free